secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001326190-26-000027
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune shareholders approve doubling authorized shares to 400M, re-elect all directors
--------------------------------------------------------------------------------

- Authorized common stock increased from 200M to 400M via certificate of amendment, approved by 63.7M for vs. 24.2M against.
- All 9 director nominees elected; broker non-votes of 35.9M on each. Highest votes for Jerome Durso at 47.6M.
- Ratification of Ernst & Young as auditor passed with 85.0M for, 1.8M against, 1.5M abstain.
- Say-on-pay advisory vote passed with 39.9M for, 12.0M against, 0.5M abstain.
- Amendment to 2019 ESPP approved to increase reserve from 403,500 to 1,108,827 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619026000027/0001326190-26-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619026000027/alt-20260416x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-26-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer